Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen

A Japanese health ministry panel on December 13 approved the reimbursement listing of Eisai’s Alzheimer’s therapy Leqembi (lecanemab). The drug’s peak sales forecast was put at 98.6 billion yen in the ninth year on the market, with 32,000 people expected...read more